Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PHGE
PHGE logo

PHGE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy BiomX Inc (PHGE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.520
1 Day change
-5.45%
52 Week Range
14.710
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BiomX Inc (PHGE) is not a good buy for a beginner, long-term investor at this time. The stock is experiencing bearish trends, lacks positive trading signals, and has significant compliance and financial challenges. Given the investor's profile and the absence of strong positive catalysts, it is better to hold off on investing in this stock.

Technical Analysis

The stock is in a bearish trend with moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 27.82, and the MACD is slightly positive but not strong enough to signal a reversal. Support and resistance levels suggest limited upside potential near-term.

Positive Catalysts

  • BiomX received NYSE approval for a compliance plan, which ensures continued operations and SEC reporting obligations.

Neutral/Negative Catalysts

  • The company has a stockholders' equity deficit of $1.302 million, ongoing losses over the past five years, and is under NYSE compliance review. This creates uncertainty for long-term investors.

Financial Performance

No financial data available for the latest quarter. However, the company reported ongoing losses and a stockholders' equity deficit as of December 31, 2025.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast PHGE stock price to rise
1 Analyst Rating
Wall Street analysts forecast PHGE stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.550
sliders
Low
26
Averages
26
High
26
Current: 0.550
sliders
Low
26
Averages
26
High
26
H.C. Wainwright
Joseph Pantginis
Buy -> Neutral
downgrade
AI Analysis
2026-03-09
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
AI Analysis
2026-03-09
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Joseph Pantginis downgraded BiomX to Neutral from Buy. BiomX has "had a rough time as of late," says the analyst, who notes that both the CEO and Chairman of the Board resigned from the company on March 6, adding "further concern about the potential path forward for the company."
H.C. Wainwright
Joseph Pantginis
Buy
upgrade
$15 -> $26
2025-11-25
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$15 -> $26
2025-11-25
upgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis adjusted the firm's price target on BiomX to $26 from $15 and keeps a Buy rating on the shares. The adjusted target follows the company's reverse stock split.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PHGE
Unlock Now

People Also Watch